The Cooper Companies heads into its June 4 Q2 report carrying a year-long weight: the stock is down roughly 25% in 2026 and has sold off sharply after each of the past two earnings prints.
The options market reflects that caution. The put/call ratio has climbed to 0.76, well above its 20-day average of 0.48 — about 1.2 standard deviations elevated — indicating hedging demand has picked up meaningfully into the release. The shift is notable in its speed: the PCR spent most of May between 0.23 and 0.28 before jumping above 0.75 in late May as the print approached. The stock closed at $60.19 on Monday, down 1.7% on the day and 3.8% on the week, extending a month that is already off 3.5%.
Short interest tells a far quieter story. At 2.6% of the free float — and falling, down 14% over the past month — dedicated short sellers are not aggressively pressing the trade into earnings. Borrowing costs are negligible at 0.5%, and borrow availability is extraordinarily loose at roughly 1,676% of short interest, meaning there are approximately 17 shares available to borrow for every one already on loan. The ORTEX short score of 34 sits in the lower half of the universe. Whatever caution exists in COO is being expressed through options, not short positioning.
The analyst community has been trimming targets in the run-up, sharpening the debate about where the floor is. Piper Sandler reiterated Overweight on June 1 but cut its target from $94 to $86. Citigroup, maintaining Neutral, moved its target down sharply to $69 from $80 just days before. The consensus mean of $88 implies roughly 46% upside from current levels — a gap that is less a vote of confidence and more a measure of how far the stock has de-rated from where analysts thought it would trade. Bulls point to CooperVision's durable market share in contact lenses, mid-single-digit organic revenue growth, and a strategic review — announced in October — that could unlock value by separating the CooperSurgical segment. Bears counter that the contact lens market faces rising competition, currency headwinds remain a drag, and any separation of the two segments risks tax dis-synergies and the loss of operational overlap. The Piotroski F-score of 8 — the highest among large-cap health care equipment peers — suggests the balance sheet is not the concern; execution and the growth trajectory are.
History gives pause. The last two earnings events each produced one-day declines of roughly 5–7%, followed by five-day losses of 12–13%. The June 4 print will test whether the 25% year-to-date drawdown has finally reset expectations enough to shift that pattern — or whether the fundamental questions around IUD demand, competitive pressure in lenses, and the strategic review timeline remain unresolved enough to extend it.
See the live data behind this article on ORTEX.
Open COO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
